Complementary and alternative medicine for treating amyotrophic lateral sclerosis: a narrative review

Mudan Cai, Eun Jin Yang

Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.

Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.

**ARTICLE INFO**

**Article history:**
Received 3 June 2019
Received in revised form 14 August 2019
Accepted 20 August 2019
Available online 29 August 2019

**Keywords:**
Amyotrophic lateral sclerosis
Complementary alternative medicine
Acupuncture
Herbal medicine

**ABSTRACT**

**Background:** Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease that is characterized by selective motor neuron cell death in the motor cortex, brainstem, and spinal cord. Two drugs for ALS, riluzole and edaravone, have been approved by FDA for the treatment of ALS patients. However, they have many side effects, and riluzole extends the patient’s life by only 2–3 months. Therefore, ALS patients seek an effective therapy for treating the symptoms or delaying the progression of ALS. Based on this, we review the effects of complementary and alternative medicine (CAM) in ALS animals or patients to verify the efficacy of CAM in incurable diseases.

**Methods:** For this review, we searched published papers focusing on the effect of CAM in pre-clinical and clinical study in ALS. The search keywords included amyotrophic lateral sclerosis, acupuncture, herbal medicine, Traditional Chinese medicine, CAM, animals, and clinical study through electronic databases PubMed and Google Scholar from their inception until March 2019.

**Results:** In the ALS animal model, CAM modulated the immune system to increase motor function by reducing the expression levels of neuroinflammatory proteins in the spinal cord. Besides this, ALS patients treated with herbal medicine showed improved disease symptoms, but clinical trials with larger sample sizes are needed to develop a treatment with herbal medicine.

**Conclusion:** This review shows that CAM may be useful for ALS treatment, but more evidence regarding the efficacy and molecular mechanisms is required to establish CAM as a good therapy for the treatment of ALS patients.

© 2019 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. **Introduction**

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily causes motor neuron death in the cerebral motor cortex, brainstem, and spinal cord, leading to restricted voluntary movement. In addition, ALS patients develop difficulty in swallowing, speaking, and breathing because of muscle paralysis.1 About 90% of ALS cases are classified as sporadic ALS (sALS). sALS results from a combination of environmental and genetic risk factors that are not well known. The remaining 10% of ALS cases are of the familial type. Around 66% of familial ALS cases have been linked to identified genetic mutations, including in chromosome 9 open reading frame 72 (C9orf72), Cu/Zn superoxide dismutase (SOD1), TAR DNA-binding protein (TARDBP), and fused in sarcoma (FUS) genes.2 The major cellular mechanisms implicated in ALS disease include disturbances in protein quality control, hyperactivation of microglia, diminished energy supply from reduced MCT (monocarboxylate transporter) 1 transporter, excitotoxicity, cytoskeletal defects, and disturbances in RNA metabolism (splicing, miRNA biogenesis, translation).3 In addition, several neurotoxic mechanisms are well known in mtSOD1-mediated ALS, such as excitotoxicity, ER stress, mitochondrial dysfunction, axon transport disruption, prion-like propagation, and non-cell autonomous toxicity of neuroglia.2 Two drugs that have been developed to address the pathological mechanism of ALS, riluzole and edaravone, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ALS patients. Riluzole (an anti-glutaminergic drug) extends the patient’s life by only about 2–3 months. The second FDA-approved drug is edaravone, an antioxidant drug which is used in Japan to assist with recovery from stroke. Although these drugs have been used for the treatment of ALS, side effects such as liver problems, serious allergic reaction (swelling of face or throat), depressed...
mood, diarrhea, fever, vomiting, dizziness, fatigue, and nausea have been reported. Therefore, there is currently no effective treatment for ALS that is able to cure or stop the progression of the disease. ALS patients and their families have begun to consider the use of complementary and alternative medicine (CAM) in order to relieve their illness and find an effective treatment.

Complementary and alternative medicine (CAM) is defined as non-mainstream treatment used together with (complementary) or in the place of (alternative) conventional medicine. The use of CAM therapy, including acupuncture, herbal medicine, and massage, yoga, relaxation therapy, and homeopathy has been popular for thousands of years in East Asia. Recently, more and more patients with chronic and incurable diseases have decided to use herbal medicine or acupuncture as part of their healthcare in the United States and in European countries. In the 2012 National Health Interview Survey (n = 33,557), more than 25% of American adults reported having two or more chronic conditions, and they often used CAM, despite limited evidence. Moreover, 54% of ALS patients reported using CAM therapy in a survey by the German Association for Neuromuscular Diseases (DGM); the most widely used methods were acupuncture, homeopathy, and naturopathy. However, there has not been any reviews covering research focused on the effects and mechanisms of CAM in ALS. Therefore, we summarized, herein, the effects of CAM and its mechanism based on published papers involving ALS animal models and patients using CAM (Table 1).

2. Methods

For this review, we searched published papers focusing on the effect of CAM in pre-clinical and clinical study in ALS. The search keywords included amyotrophic lateral sclerosis (or ALS), acupuncture, herbal medicine, Traditional Chinese medicine (or TCM), CAM, animals, clinical study through Pubmed, Google Scholar electronic databases from their inception until March, 2019.

3. Use of CAM for amyotrophic lateral sclerosis

The summarized information of CAM for ALS is shown in Table 1.

3.1. Acupuncture for ALS

Acupuncture is one of type of CAM and has also been widely used in Korea, China, and Japan for centuries. Acupuncture needles (thin needles) are inserted into certain locations (called acupoints) of the body. Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin. Acupuncture is widely used for musculoskeletal problems, particularly chronic pain or neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Generally, acupuncture is protective, or improves the phenotypes (cognitive function in AD, tremor in PD) through brain functional activity in neurodegenerative diseases.

In the case of ALS, some papers have demonstrated the effects of EA treatment in the spinal cord and lung of a symptomatic ALS animal model. Yang et al. showed that EA at Zusanli (ST36) improved motor function and reduced neuronal cell loss through the reduction of microglial cells and the expression of TNF-α in the brainstem and spinal cord of hSOD1G93A animals. In addition, EA treatment also reduced the levels of pro-inflammatory cytokines (TNF-α and IL-6) and increased cell survival-related protein (pAKT and pERK) expression in the lung of hSOD1G93A animals. These studies suggest that EA treatment could be helpful in increasing anti-inflammation activity in the central nervous system (CNS) and respiratory system of ALS animals.

Saam acupuncture is one of type of acupuncture based on the traditional concepts of yin–yang, five elements (Wood, Fire, Earth, Metal, and Water), ZangFu (viscera and bowels), qi, and meridians, and is representative of traditional Korean medicine. Korean saam acupuncture has lung tonification effects, which were investigated in this study through the analysis of Korean traditional literature. Lee et al. showed that saam acupuncture treatment at Taibai (SP3), Taiyuan (LU9), Shaofu (HT8), and Yuji (LU10) acupoints regulated respiratory physiology parameters in ALS patients. Patients who had high Korean Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised (K-ALSFRS-R) scores had greater changes in pulse rate after acupuncture stimulation. In addition, saam acupuncture decreased end-tidal carbon dioxide (EtCO2), respiratory rate (RR), and pulse rate, and increased the peripheral oxygen saturation (SpO2) in ALS patients. Therefore, the authors suggested that saam acupuncture would be more effective in early stages of the disease to increase the effects of treatment using saam acupuncture.

3.2. Herbal medicine for ALS

Herbal medicine is a part of CAM therapy defined as the utilization of herbs, animals, and minerals commonly used in East Asia. Herbal medicine contains hundreds of components and targets multiple pathways. Based on holistic concepts and dialectical theory, herbal medicine has been used for over two thousand years.

3.2.1. Bee venom

Bee venom (BV), also called apitoxin, is extracted from honeybees and contains enzymes, lipids, amino acids, carbohydrates, and peptides such as melittin, apamin, phospholipase A2 (PLA2), and hyaluronidase. BV has been mainly used for rheumatic disease for anti-inflammatory effects in human and mice models. In addition, phospholipase of BV enhanced the cognitive function, increased glucose metabolism, and decreased Aβ deposit by microglial deactivation and reduction of CD4 (+) T cell infiltration in an AD mouse model, and for its protective effect on dopaminergic neurons in a PD mouse model. In the case of ALS, Kim et al. demonstrated that BV treatment recovered proteasome activity and attenuated the accumulation of misfolded SOD1 in mtSOD1-overexpressing NSC34 motor neuronal cells. In an ALS animal model, Yang et al. demonstrated that BV treatment improved motor activity and increased survival by reducing neuroinflammation in the spinal cord and brainstem of hSOD1G93A mice. In addition, BV treatment suppressed the expression of active caspase-3 protein and inhibited mitochondrial structure impairment in the lumbar of the spinal cord of hSOD1G93A at the symptomatic stage. Furthermore, Cai et al. and Lee et al. reported anti-inflammatory effects of BV at acupoints. In this study, the authors considered BV treatment via two ways (the ST36 acupoint or intraperitoneal (i.p.) injection) and investigated BV’s effects on the CNS and peripheral organs, such as the liver, kidney, and spleen of symptomatic hSOD1G93A animals. BV treatment at the ST36 acupoint increased the anti-neuroinflammation effect compared to BV treatment by i.p. injection via a decrease in the level of TLR4-inflammatory signaling-pathway-related proteins (TLR4, CD14, and TNF-α) in the spinal cord of hSOD1G93A mice. In addition, Lee et al. showed that inflammation-related proteins (Iba-1, COX2, and TNF-α) were significantly reduced by BV treatment at the ST36 acupoint compared to i.p. injection of BV in the peripheral organs such as the liver, spleen, and kidney of ALS mice. Taken together, this indicates that BV treatment would be useful for improvement of the immune system in the CNS and peripheral nervous system (PNS), at least in hSOD1G93A ALS animals.

Melittin (MT) is a major component of BV. Yang et al. investigated the effect of MT in BV to characterize the bioactive component.
Table 1
Summary of the effects of complementary and alternative medicine (CAM) used in ALS.

| CAM modality | Type of study | Method | Effectiveness | Author (year) |
|--------------|---------------|--------|---------------|---------------|
| Electroacupuncture (EA) | Animal | Zusani (ST36) acupoint, (1 mA, 2 Hz, 30 min), 6 times | (Spinal cord) Increased motor activity, neuronal protection, and anti-neuroinflammation | Yang (2010) |
| Electroacupuncture (EA) | Animal | Zusani (ST36) acupoint, (1 mA, 2 Hz, 30 min), 6 times | (Lung) Reduced pro-inflammatory cytokines, and increased cell survival-related protein | Jiang (2010) |
| Saam acupuncture | Clinical | Taibai (SP3), Taiyuan (LU9), Shaofu (HT8), and Yuji (LI10) twice a day for 5 days | Regulated respiratory physiology | Lee (2013) |
| Bee venom (BV) | Animal | 0.1 μg/g, Zusani (ST36), 14 times | (Brainstem and spinal cord) Increased motor activity, survival, anti-inflammation, and neuronal protection | Yang (2010) |
| Melittin (MT) | Animal | 0.1 μg/g, Zusani (ST36), 14 times | (Brainstem and spinal cord) Increased motor activity, anti-neuroinflammation, and proteasome activity | Yang (2011) |
| Melittin (MT) | Animal | 0.1 μg/g, Zusani (ST36), 14 times | (Lung) Increased anti-inflammation (Spleen) Increased anti-inflammation and cell survival | Lee (2014) |
| Scolopendra subspinipes mutilans (SSM) | Animal | 2.5 μg/g, Zusani (ST36), 6 times | (Brainstem and spinal cord) Increased neuronal protection, anti-inflammation, and anti-oxidation | Cai (2013) |
| Ginsenoside Re (G-Re) | Animal | 2.5 μg/g, Zusani (ST36), 6 times | (Spinal cord) Increased neuronal protection, anti-inflammation, and anti-oxidation | Cai (2016) |
| Withania somnifera | Animal | 5 mg/per animal, p.o., 8 or 16 weeks | (Gastrocnemius muscle and spinal cord) Increased motor activity, cognitive function, muscle innervation. Anti-inflammation, anti-NF-κb activation Decreased mislocalization and aggregation of TAR DNA-binding protein 43 (TDP43) | Dutta (2017) |
| Bojungkgi-tang (BJGT) | Animal | 1 mg/g, p.o., 6 weeks | (Spinal cord and gomastocenuis muscle) Increased motor activity, survival, anti-inflammation, and anti-oxidation Decreased autophagy dysfunction, muscle atrophy, and denervation of neuromuscular junctions | Cai (2018) |
| Gamisoyo-San (GSS) | Animal | 1 mg/g, p.o., 6 weeks | (Spinal cord) Increased neuronal protection, anti-inflammation, and anti-oxidation Decreased metabolism dysfunction (Gastrocnemius muscle) Increased anti-inflammation and anti-oxidation | Cai (2018) |
| Gamisoyo-San (GSS) | Animal | 1 mg/g, p.o., 6 weeks | (Gastrocnemius muscle) Increased anti-inflammation and anti-oxidation | Park (2018) |
| Jaeumgangwa-Tang (JGT) | Animal | 1 mg/g, p.o., 6 weeks | (Spinal cord) Increased motor function, anti-inflammation, and anti-oxidation | Lee (2019) |
| Huolingshengji Formula (HLSJ) | Animal | 4.5 g/kg d. p.o., 100 days | (Spinal cord, Gastrocnemius muscle) Increased motor activity and survival, anti-apoptosis and anti-inflammation, Decreased muscle atrophy | Zhou (2018) |
| Huolingshengji Formula (HLSJ) | Clinical | 200 ml, p.o., 12 weeks | Decreased Advanced Norris scale score (ANSS) Improved TCM syndrome Increased survival, muscle fibrillation, and muscle strength Delayed use of ventilator support Fewer adverse effects | Sui (2016) |
| Dihuang Yinzi (DHYZ) | Clinical | Decoction, p.o., twice daily, 12 years | Decreased immunosuppression according to the ALS functional rating scale (ALSFRS) | Qiu (2016) |
| Jiawei Sijunzi (JWSZ) | Clinical | Decoctions, p.o., 50 ml, twice daily | Improved neurologic evaluation and quality of life (QoL) | Pan (2013) |
| Creatine | Animal | 2% creatine-fed, 4 weeks | Improved motor performance, weight maintenance, and survival | Andreassen (2001) |
| Creatine | Animal | 2% creatine-fed, 60 days | No effect on muscle metabolic parameters, muscle weight, muscle contractile parameters, and fatigue | Derave (2003) |
| Vitamin D | Clinical | 2000 IU/day, 9 months, daily | Decreased revised ALS functional rating scale (ALSFRS-R) score Decreased disease onset and slow progression | Pastula (2012) |
| Vitamin E | Animal | 200 IU/kg of mouse chow, Treatment continued until end-stage disease | Decreased disease onset and slow progression | Karam (2013) |

ALS, Amyotrophic lateral sclerosis; ALSFRS, ALS functional rating scale; ALSFRS-R, revised ALS functional rating scores; ANSS, Advanced Norris scale score; TCM, Traditional Chinese Medicine.

Providing anti-neuroinflammation effects in ALS animals. They demonstrated that MT treatment restored proteasome function and modulated the levels of inflammation-related proteins (Iba-1 and TNF-α) in the spinal cord and brainstem of hSOD1(G93A) animals. In addition, MT treatment showed anti-inflammation effects in the lung and spleen through the reduction of Iba-1, CD14, TNF-α, and COX2 proteins in hSOD1(G93A) ALS animals.
3.2.2. *Scolopendra subspinipes mutilans* 

*Scolopendra subspinipes mutilans* (SSM) is utilized in traditional Chinese medicine, and the compounds contained in SSM have many biological effects, including anticancer,25 immunomodulatory,26 antimicrobial,7 and antifungal activities.26 Based on a previous study, Cai et al. investigated the effects of SSM in SOD1G93A mice, and showed anti-inflammation effects due to the reduction of microglial cells and astrocytes, and antioxidant effects due to decreases in CD14, HO-1, and NQO1 protein levels in the brainstems and spinal cords of hSOD1G93A.29

3.2.3. Ginseng 

Ginseng is well known as a traditional herbal medicine and has various effects, including antifatigue and antiaging effects, and can induce improved immunity.30 Ginseng is composed of various substances, including proteins, carbohydrates, ginsenosides (ginseng saponins), amino acids, vitamins, and fatty acids. In particular, ginsenosides are classified as protopanaxadiols (PPD; e.g., Ra, Rb, Rc, Rd, Rg3, Rh2) and protopanaxatriols (PPT; e.g., Re, Rf, Rg1, Rg2, Rh1).31 Lee et al. demonstrated that pretreatment with Ginsenoside Re (G-Re) has a neuroprotective effect against lipopolysaccharides (LPS)-induced microglial cell lines through inhibition of the expression of pp38, iNOS, and COX2 proteins.33 Furthermore, G-Re treatment attenuated motor neuron loss through the reduction of neuroinflammation-related proteins (Iba-1, GFAP, CD14, and TNF-α) and oxidative-stress-related proteins (pp38 and HO-1) in the lumbar spinal cord of hSOD1G93A animals.34

*Withania somnifera*, also called Indian ginseng, has been utilized in the traditional Indian medical system. *Withania somnifera* has demonstrated antimicrobial, anti-inflammatory, antineoplastic, antistress, cardioprotective, antiadiabetic, and neuroprotective properties in multiple disease models, including of AD, PD, Huntington's disease (HD), and spinal cord injuries.53 Dutta et al. demonstrated that treatment with a *Withania somnifera* root extract led to improved motor function, cognitive function, and neuromuscular junction (NMJ) innervation, and reduced neuroinflammation and NF-κB activation. Moreover, this treatment was found to reverse human TAR DNA-binding protein 43 (hTDP43) cytoplasmic mislocalization and reduce hTDP43 aggregation in the spinal cord motor neuron and cortical neurons of hTDP43ALS mice.37

3.2.4. Traditional herbal prescription 

Traditional herbal prescription is a common form of CAM therapy and has been used for various diseases according to traditional Chinese medicine (TCM) theory or Korean medicine (KM) theory.

Bojungikgi-tang (BJJGT), known as Bu-Zhong-Yi-Qi-Tang in Chinese medicine and Houchuikko in Japan, is used for the improvement of immune function in allergic rhinitis.38,39 In an ALS spinal model, BJIGT enhanced motor activity and extended survival rate through the induction of anti-neuroinflammation and antioxidant effects in the spinal cord and gastrocnemius of hSOD1G93A animals.40 Furthermore, this study showed that BJJGT treatment prevented muscle atrophy and the denervation of neuromuscular junctions in the gastrocnemius of ALS hSOD1G93A mice.40

Gamisooyo-San (GSS) has often been used as an herbal prescription to improve stress-related neuropsychological disorders, anorexia, insomnia, functional dyspepsia dysmenorrhea, and infertility.41,42 Cai et al. observed that GSS decreased the expression of microglial cells and astrocytes, and prevented neuronal loss in the spinal cord of ALS mice.43 Furthermore, GSS attenuated the expression levels of oxidative-stress-related proteins (transferrin, HO-1, and BAX) and metabolism dysfunction in the spinal cord of ALS animals.45 Park et al. demonstrated that GSS ameliorated inflammation through the inhibition of inflammatory proteins (TLR4 and CD11b) in the gastrocnemius in hSOD1G93A.44

Jaeumganghwa-Tang (JGT) is useful for the treatment of bronchitis and tuberculosis45 and anti-allergic inflammatory responses.46 In ALS animals, Lee et al. showed that JGT treatment improved motor function using a footprint behavior test. They found that JGT treatment decreased the levels of inflammatory proteins (Iba-1, TLR4, and TNF-α) and oxidative-stress-related proteins (transferrin, ferritin, HO1, and NQO1) in the spinal cord of ALS mice.47 From these data, we can see that herbal prescriptions such as BJJGT, GSS, and JGT would be helpful in improving the immune response and delaying disease progress in ALS.

Huolingshengji (HLSJ) improves vital energy (Qì) and the function of spleen and kidney, and invigorates yang in order to relieve the TCM pathogenesis of flaccid syndrome.48 Zhou et al. demonstrated that HLSJ increased the lifespan and prevented motor neuron loss through ameliorating muscle atrophy and inflammatory effects in SOD1G93A ALS mice.48 In addition, Sui et al. showed that HLSJ treatment for 12 weeks decreased the Advanced Norris scale score in ALS patients. Moreover, the total effective rate in the HLSJ-treated ALS patients (15.15%) was similar to that in the riluzole-treated group (16.13%). In addition, TCM syndrome was significantly improved in HLSJ-treated ALS patients (33.33%) compared to in the riluzole-treated group (6.45%). These data suggest that HLSJ may be an effective therapy for ALS.49

Dihuang Yinzi (DHYZ) is a classical traditional Chinese medicine (TCM) prescription. DHYZ is used for treating neurological disorders, like speech and language impairment and motor paralysis. In a case report, Qiu et al. showed that DHYZ extended the survival and improved symptoms of muscle fibrillation and low muscle strength in a female ALS patient. This result suggested that DHYZ could be helpful for the treatment of ALS patients, and further rigorous randomized controlled trials are needed.50

Jiawei Sijunzi (JWSJZ) is a famous traditional decoction which nourishes the spleen and enriches body vitality.51 JWSJZ treatment for 3 or 6 months resulted in improved neurologist evaluation of ALS patients through the ALS functional rating scale (ALSFRS), compared with prior to the treatment.51 These data suggest that the JWSJZ decoction may be safely used to treat ALS and delay the disease progression.

3.3. Other types CAMs for ALS

Nutritional supplements, massage, and relaxation techniques are also included in the most commonly considered CAM therapies. Most of the currently used nutritional supplements, including vitamins, minerals, proteins, and amino acids, have antioxidant properties. Nutritional supplements provide nutrients and remedy deficiencies in the body. The beneficial effects of using nutritional supplements in treating ALS have been demonstrated in both preclinical and clinical studies.

Creatine was synthesized in the kidney and liver, and then transported to the muscles and brain via blood for energy production. In an ALS animal model, creatine treatment improved motor function, maintained body weight, and extended survival.52 However, another study showed that creatine treatment was not effective for improvement of muscle function in ALS animals.53 In the clinical study, creatine intake at doses 5–10 g per day did not extend survival, ALSFRS-R progression, or the percentage of predicted forced vital capacity (FVC) progression.54

Vitamin D is a fat-soluble secosteroids and helps in increasing intestinal absorption of calcium, magnesium, and phosphate. In ALS patients, Camu et al. reported that the risk of death was 4 times increase in those with severe vitamin D deficiency group compared to the group with normal vitamin D group.55 In addition, another clinical study showed that patients with ALS were detected low
level of vitamin D. Patients taking 2000 international units (IU) of vitamin D daily declined ALSFRS-R score in the 9 months but was not significant at 3 or 6 months.56

Vitamin E as a fat-soluble antioxidant includes four tocopherols and four tocotrienols. In ALS transgenic mice, treatment with vitamin E delayed disease onset and slowed progression, but did not prolong survival.57 Gaf et al. could not demonstrate the efficacy of vitamin E therapy in ALS patients.58 However, Wang et al. interestingly showed that vitamin E intake may reduce the risk of developing ALS.59 Therefore, the effect of vitamin E in ALS patients is controversial, but it should be used with caution since hypervitaminosis E could increase the risk of bleeding.60

To investigate the use of CAM therapy in the treatment of ALS in China, Pan et al. surveyed 12 hospitals in Shanghai. This study reported that 229 (99% of the total) of 231 (qualified people) used at least one CAM therapy for the treatment of ALS. Vitamins and Chinese herb decoctions, Chinese herbal compounds, massage therapy, and acupuncture were the five most commonly used therapies.61 In addition, Pan et al. showed that CAM therapy alleviated weakness and fatigue, muscle atrophy to inhibit ALS progression and side effects associated with riluzole.62

4. Summary of the effects of CAM therapy in ALS

This review summarized the effects of CAM therapy in ALS human and animal models (Table 1). Several types of CAM are used for treating ALS including acupuncture and herbal medicines. In ALS patients and animal models, acupuncture or electroacupuncture (EA) improved motor activity and the pulmonary system. This suggests that acupuncture could be helpful for increasing the body’s vital energy, which is connected to bodily organs and functions, and circulates throughout the body via the meridian system, because ALS patients are deficient in qi, according to the theory of oriental medicine.62

In ALS animal models, herbal medicine modulates the immune system to protect motor neurons and motor activity. Herbal medicine may regulate immune function in the spinal cord, brainstem, lung, spleen, and muscle through inhibiting proinflammatory cytokines and glial cell activation. In a clinical study, an herbal medicine formula improved disease symptoms according to a neurological evaluation, but the sample size was too small to evaluate the effects of CAM therapy.

ALS has multiple pathological mechanisms, such as neuroinflammation, oxidative stress, glutamate excitotoxicity, protein misfolding, cytoskeletal abnormalities, defective axonal transport, and inadequate growth factor signaling, leading to motor neuron death and muscle paralysis. Since herbal medicine contains various components which display multiple effects, it would be helpful in alleviating the pathological phenomena affecting patients with ALS, and in this way, increase the quality of life for the families of patients. However, more researches must be performed regarding the efficacy and safety of CAM therapy, and clinical studies will be required to demonstrate the effects of CAM therapy in ALS.

Author contributions
MC searched the papers and drafted the manuscript; EJY conceptualized the review; searched for additional information and revised critically; MC & EJY read the final manuscript and agreed to the submission.

Conflict of interest
The authors declare no conflict of interest.

Funding
This study was supported by the Korea Institute of Oriental Medicine (KIOM) under Grant C18040.

Ethical statement
Not applicable.

Data availability
Data will be made available upon request. All data used for this study are from previous studies which are included in References.

References
1. Taylor JF, Brown JR, Cleveland DW. Decoding ALSs: from genes to mechanism. Nature 2016;539(7628):197–206.
2. Hayashi Y, Homma K, Ichiho H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv Biol Regul 2014;60:95–104.
3. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD004147.
4. Kim S, Chung SE, Lee S, Park J, Choi S, Kim S. Experience of complementary and alternative medicine in patients with amyotrophic lateral sclerosis and their families: a qualitative study. Amyotroph Later Scler Frontotemporal Degener 2016;17(3–4):191–7.
5. Falchi, Shiz, Greenlee H. Multiple chronic conditions and use of complementary and alternative medicine among US adults: Results from the 2012 national health interview survey. Prev Chronic Dis 2016;13:E61.
6. Wagner M, Kies H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 2001;191(1–2):151–4.
7. Zhang R, Lao L, Ren K, Berman BM. Mechanisms of acupuncture-electroacupuncture on persistent pain. Anesthesiology 2016;120(2):482–503.
8. Liang P, Wang Z, Qian T, Li K. Acupuncture stimulation of Taichong (Liv3) and Hegu (LI4) modulates the default mode network activity in Alzheimer’s disease. Am J Alzheimers Dis Other Demens 2014;29(8):739–48.
9. Lin JG, Chen CJ, Yang HB, Chen YH, Hung SY. Electroacupuncture promotes recovery of motor function and reduces dopaminergic neuron degeneration in rodent models of Parkinson’s disease. Int J Mol Sci 2017;18(9).
10. Jiang JH, Yang EF, Baek MG, Kim SH, Lee SM, Choi SM. Anti-inflammatory effects of electroacupuncture in the respiratory system of a symptomatic amyotrophic lateral sclerosis animal model. Neurodegener Dis 2011;8(6):504–14.
11. Yang EF, Jiang JH, Lee SM, Hwang HS, Lee MS, Choi SM. Electroacupuncture reduces neuroinflammatory responses in symptomatic amyotrophic lateral sclerosis model. J Neuroimmunol 2010;223(1–2):84–91.
12. Park M, Kim S. A modern clinical approach of the traditional Korean saam acupuncture. Evid Based Complement Alternat Med 2015;2015, 703439.
13. Lee S, Kim S. The effects of sa-am acupuncture treatment on respiratory physiology parameters in amyotrophic lateral sclerosis patients: a pilot study. Evid Based Complement Alternat Med 2013;2013:506317.
14. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-relieving, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol Ther 2007;115(2):246–70.
15. Eiseman JL, von Bredow J, Alvaro AP. Effect of honeybee (Apis mellifera) venom on the course of adjunct-induced arthritis and depression of drug metabolism in the rat. Biochem Pharmacol 1982;31(6):1139–46.
16. Billingham ME, Morley J, Hanson JM, Shipolini RA, Vernon CA. Letter: an anti-inflammatory peptide from bee venom. Nature 1973;245(5421):163–4.
17. Ye M, Chung HS, Lee C, Yoon MS, Yu AR, Kim JS, et al. Neutrophilic effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease. J Neuroinflammation 2016;13:10.
18. Alvarez-Fischer D, Noecker C, Vulinovic F, et al. Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PLoS One 2013;8(4):e61700.
19. Kim SH, Jung SY, Lee KW, et al. Bee venom effects on ubiquitin proteasome system in SOD1(G93A)-expressing NSC34 motor neuron cells. BMC Complement Altern Med 2013;13:179.
20. Yang EF, Jiang JH, Lee SM, et al. Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models. J Neuroinflammation 2010;7:69.
21. Cai M, Choi SM, Yang EF. The effects of bee venom acupuncture on the central nervous system and muscle in an animal SOD1(G93A) mutant. Toxins (Basel) 2015;7(7):454–58.
22. Lee SH, Choi SM, Yang EF. Bee venom acupuncture augments anti-inflammation in the peripheral organs of SOD1(G93A) transgenic mice. Toxins (Basel) 2015;7(8):2835–44.
23. Yang EF, Kim SH, Yang SC, Lee SM, Choi SM, Melitinin restores proteasome function in an animal model of ALS. J Neuroinflammation 2011;8:69.
24. Lee SH, Choi SM, Yang EF. Melitinin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model. Exp Neurobiol 2014;23(1):86–92.
25. Lee JH, Kim IW, Kim SH, et al. Anticancer activity of the antimicrobial peptide scolopendin-1 derived from the centipede Scolopendra subspinipes mutans. J Microbiol Biotechnol 2015;25(8):1275–80.

26. Park YJ, Lee HY, Jung YS, Park JS, Hwang JS, Bae YS. Antimicrobial peptide scolopendin VII derived from the centipede Scolopendra subspinipes mutans stimulates macrophage chemotaxis via formyl peptide receptor 1. BMB Rep 2015;48(8):479–84.

27. Kwon YN, Lee JH, Kim IW, et al. Antimicrobial activity of the synthetic peptide scolopendin III from the centipede Scolopendra subspinipes mutans. J Microbiol Biotechnol 2012;23(10):1381–5.

28. Choi H, Hwang JS, Lee DG. Identification of a novel antimicrobial peptide, scolopedin 1, derived from centipede Scolopendra subspinipes mutans and its antifungal mechanism. Insect Mol Biol 2014;23(6):788–99.

29. Cai M, Choi SM, Song BK, Son I, Kim S, Yang EJ. Scolopendra subspinipes mutans attenuates neuroinflammation in symptomatic hSOD1(G93A) mice. J Neuroinflammation 2013;10:131.

30. Chu SF, Zhang JT. New achievements in ginseng research and its future prospects. Chin J Integr Med 2009;15(6):403–8.

31. Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 2008;29(9):1109–18.

32. Yang Y, Ren C, Zhang Y, Ginseng Wu X. An nonnegligible natural remedy for healthy aging. Aging Dis 2017;8(6):708–20.

33. Lee KW, Jung SY, Choi SM, Yang EJ. Effects of ginsenoside Re on LPs-induced inflammatory mediators in BV2 microglial cells. BMC Complement Altern Med 2012;12:196.

34. Cai M, Yang EJ. Ginsenoside Re attenuates neuroinflammation in a symptomatic ALS animal model. Am J Chin Med 2016;44(4):401–13.

35. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 2000;5(4):334–46.

36. Kuboyama T, Touda C, Komatsu K. Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. Biol Pharm Bull 2014;37(6):892–7.

37. Dutta K, Patel P, Rahimian R, Phaneuf D, Julien JP. Withania somnifera reverses transactive response DNA binding protein 43 proteinopathy in a mouse model of amyotrophic lateral sclerosis/Frontotemporal lobar degeneration. Neurotherapeutics 2017;14(2):447–62.

38. Yamaoka Y, Kawakita T, Nomoto K. Protective effect of a traditional Japanese medicine, Bu-zhong-yi-qian (Japanese name: Hochu-ekki-to), on the restraint stress-induced susceptibility against Listeria monocytogenes. Immunopharmacology 2000;48(1):35–42.

39. Lee MY, Shin IS, Jeon WY, et al. Protective effect of Boujungki-tang, a traditional herbal formula, against alcohol-induced gastric injury in rats. J Ethnopharmacol 2012;142(2):346–53.

40. Cai M, Lee SH, Yang EJ. Boujungki-tang improves muscle and spinal cord function in an amyotrophic lateral sclerosis model. Mol Neurobiol 2019;56(4):2394–407.

41. Shin SJ, Kim D, Kim JH, et al. Effects of gamsioyo-san decoction, a traditional Chinese medicine, on gastrointestinal motility. Digestion 2018;98(4):231–7.

42. Jin SE, Kim OS, Yoo SK, et al. Anti-inflammatory effect and action mechanisms of traditional herbal formula Gamsioyo-san in RAW 264.7 macrophages. BMC Complement Altern Med 2016;16:219.

43. Cai M, Yang EJ. Gamsioyo-san ameliorates neuroinflammation in the spinal cord of hSOD1(G93A) transgenic mice. Mediators Inflamm 2018;2018, 5897617.

44. Park S, Yang EJ. Anti-inflammatory effect of Gamsioyo-San in an animal model of amyotrophic lateral sclerosis. Evid Based Complement Alternat Med 2018;2018, 8580152.

45. Sekiya N, Hikiami H, Sakai S, et al. Experimental application of Juin-koka-to to cases of bronchial asthma. Kampo Med 2003;54(6):1097–101.

46. Kim Y, Kim H, Kim W, et al. Inhibitory effect of Juanganghwa-tang on allergic inflammatory reaction. J Intern Korean Med 2004;25(2):174–82.

47. Lee SH, Yang EJ. Anti-neuroinflammatory effect of Jaemungshengwa-tang in an animal model of amyotrophic lateral sclerosis. Evid Based Complement Alternat Med 2019;2019, 1893526.

48. Zhou Q, Wang Y, Zhang J, et al. Fingerprint analysis of Huoilingshengji Formula and its neuroprotective effects in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Sci Rep 2018;8(1):1688.

49. Su S, Wang Y, Zhi H, Hong Y, Feng Y. Effect of “Huoiling Shengji Formula” in treatment of amyotrophic lateral sclerosis. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologicae Shanghai 2016;30(2):23–6.

50. Qiu H, Li JH, Yin SR, Ke JQ, Qiu CI, Zheng QG, Dihuang yinzi, a classical chinese herbal prescription, for amyotrophic lateral sclerosis: a 12-year follow-up case report. Medicine (Baltimore) 2016;95(14):e3324.

51. Pan W, Su X, Bao J, et al. Open randomized clinical trial on JWSJJ decoction for the treatment of ALS patients. Evid Based Complement Alternat Med 2013;2013:347525.

52. Andreasen OA, Jenkins BG, Dedegolu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001;77(2):383–90.

53. Derave W, Van Den Bosch L, Lennemans G, Eijnde BO, Robberecht W, Hespel P. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis 2003;13(3):264–72.

54. Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;12. CD005225.

55. Camu W, Tremblier B, Plassot C, et al. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging 2014;35(5):1198–205.

56. Karam C, Barrett MJ, Imperato T, MacGowan DJ, Scelsa S, Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci 2013;20(11):1550–3.

57. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39(2):147–57.

58. Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study. J Neural Transm (Vienna) 2005;112(5):649–60.

59. Wang H, O’Reilly EJ, Weisskopf MG, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol 2011;173(6):595–602.

60. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids; 2000. Washington (DC)

61. Pan W, Chen X, Bao J, et al. The use of integrative therapies in patients with amyotrophic lateral sclerosis in Shanghai, China. Evid Based Complement Alternat Med 2013;2013, 613596.

62. Zhu J, Shen L, Lin X, Hong Y, Feng Y. Clinical research on traditional chinese medicine compounds and their preaparations for amyotrophic lateral sclerosis. Biomed Pharmacother 2017;96:854–64.